Lunesta

Lunesta is a brand name of eszopiclone, approved by the FDA in the following formulation(s):

LUNESTA (eszopiclone - tablet; oral)

• 
  Manufacturer: SUNOVION PHARMS INC
  
  Approval date: December 15, 2004
  
  Strength(s): 1MG, 2MG, 3MG ^[RLD]

Has a generic version of Lunesta been approved?

No. There is currently no therapeutically equivalent version of Lunesta available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Lunesta. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Optically active 5H-pyrrolo[3, 4-B]pyrazine derivative, its preparation and pharmaceutical compositions containing it
  Patent 6,319,926
  Issued: November 20, 2001
  Inventor(s): Cotrel; Claude & Roussel; Gerard
  Assignee(s): Sepracor Inc.
  Dextrorotatory isomer of 6-(5-chloro-2-pyridyl)-5[(4-methyl-1-piperazinyl)carbonyloxy]-7-oxo-6,7-di hydro-5H-pyrrolo[3,4-b]pyrazine, its preparation and pharmaceutical compositions containing it which are usable as tranquillizers and hypnotics.
  
  Patent expiration dates:
  
  
  • January 16, 2012
    
    ✓ 
    Patent use: TREATMENT OF INSOMNIA
  
  



• 
  Optically active 5H-pyrrolo[3,4-b]pyrazine derivative, its preparation and pharmaceutical compositions containing it
  Patent 6,444,673
  Issued: September 3, 2002
  Inventor(s): Claude; Cotrel & Gérard; Roussel
  Assignee(s): Sepracor Inc.
  Dextrorotatory isomer of 6-(5-chloro-2-pyridyl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazine, its preparation and pharmaceutical compositions containing it which are usable as tranquillizers and hypnotics.
  
  Patent expiration dates:
  
  
  • February 14, 2014
    
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  



• 
  Optically active 5H-pyrrolo[3,4-b]pyrazine derivative, its preparation and pharmaceutical compositions containing it
  Patent 6,864,257
  Issued: March 8, 2005
  Inventor(s): Cotrel; Claude & Roussel; Gérard
  Assignee(s): Sepracor Inc.
  Dextrorotatory isomer of 6-(5-chloro-2-pyridyl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazine, its preparation and pharmaceutical compositions containing it which are usable as tranquillisers and hypnotics.
  
  Patent expiration dates:
  
  
  • August 30, 2012
    
    ✓ 
    Patent use: METHOD OF INDUCING A HYPNOTIC OR SEDATIVE EFFECT IN A HUMAN BY ADMINISTERING ESZOPICLONE
  
  



• 
  Optically active 5H-pyrrolo[3,4-b]pyrazine derivative, its preparation and pharmaceutical compositions containing same
  Patent 7,381,724
  Issued: June 3, 2008
  Inventor(s): Cotrel; Claude & Roussel; Gerard
  Assignee(s): Sepracor Inc.
  Dextrorotatory isomer of 6-(5-chloro-2-pyridyl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazine, its preparation and pharmaceutical compositions containing it which are usable as tranquillisers and hypnotics.
  
  Patent expiration dates:
  
  
  • January 16, 2012
    
    ✓ 
    Patent use: METHOD OF INDUCING A HYPNOTIC OR SEDATIVE EFFECT IN A HUMAN BY ADMINISTERING ESZOPICLONE
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  

See also...

• Lunesta Consumer Information (Drugs.com)
• Lunesta Consumer Information (Wolters Kluwer)
• Lunesta Consumer Information (Cerner Multum)
• Lunesta Advanced Consumer Information (Micromedex)
• Lunesta AHFS DI Monographs (ASHP)
• Eszopiclone Consumer Information (Wolters Kluwer)
• Eszopiclone Consumer Information (Cerner Multum)
• Eszopiclone Advanced Consumer Information (Micromedex)
• Zopiclone Advanced Consumer Information (Micromedex)
• Eszopiclone AHFS DI Monographs (ASHP)